Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M6GC
|
|||
| Former ID |
DIB007271
|
|||
| Drug Name |
TRU-015
|
|||
| Synonyms |
CytoxB20G; XXX_CytoxB20G; CD20 antagonist, Trubion; PF-5212374
Click to Show/Hide
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 2 | [1] | |
| Company |
Trubion Pharmaceuticals Inc; Trubion
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | Antagonist | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00634933) Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis. U.S. National Institutes of Health. | |||
| REF 2 | TRU-015, a small modular immunopharmaceutical (SMIP drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis. Arthritis Res Ther. 2007; 9(Suppl 3): P32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.